Vikram P. Sinha
Pharmaceutical Research and Manufacturers of America · 96 works · 3,206 citations · h-index 27
Top works
- Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
- Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation
- Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
- Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
- Model-Based Drug Development: The Road to Quantitative Pharmacology
- Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
- A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
- PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways
- Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes
- In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
- Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA
- Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G‐CSF in Breast Cancer Patients
- The future is now: Model‐based clinical trial design for Alzheimer's disease
- Fluoxetine Pharmacokinetics in Pediatric Patients
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
- Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy
- A proposal for scientific framework enabling specific population drug dosing recommendations
- A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.